Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies

Vincent M. Perez, Joseph F. Kearney, Jen Jen Yeh

Frontiers in Oncology · 2021 · Review · CC BY

doi:10.3389/fonc.2021.751311

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is notorious for a dense fibrotic stroma that is interlaced with a collagen-based extracellular matrix (ECM) that plays an important role in tumor biology. Traditionally thought to only provide a physical barrier from host responses and systemic chemotherapy, new studies have demonstrated that the ECM maintains biomechanical and biochemical properties of the tumor microenvironment (TME) and restrains tumor growth. Recent studies have shown that the ECM augments tumor stiffness, interstitial fluid pressure, cell-to-cell junctions, and microvascularity using a mix of biomechanical and biochemical signals to influence tumor fate for better or worse. In addition, PDAC tumors have been shown to use ECM-derived peptide fragments as a nutrient source in nutrient-poor conditions. While collagens are the most abundant proteins found in the ECM, several studies have identified growth factors, integrins, glycoproteins, and proteoglycans in the ECM. This review focuses on the dichotomous nature of the PDAC ECM, the types of collagens and other proteins found in the ECM, and therapeutic strategies targeting the PDAC ECM.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

With a 5-year survival of 10%, pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of cancer deaths in the United States and is projected to become the second leading cause of cancer deaths in the United States by 2030. Most patients have regional or distant spread at the time of diagnosis and are not eligible for a potentially curative operation. While advances have been made in the treatment of metastatic PDAC, most patients remain refractory to current regimens. Metastatic PDAC exhibits resistance to therapies like cytotoxic, radiation, and molecularly targeted therapies. A major factor thought to contribute to the treatment resistance of PDAC is its dense fibrotic stroma intertwined with the extracellular matrix (ECM), which together, provide a physical barrier of protection to the tumor cells and may also restrain tumor growth.

Research has shown that the ECM plays several roles beyond acting as a barrier for tumor cells. The deposition of abundant ECM proteins is common among solid tumors like PDAC and is known as a desmoplastic reaction. This tumor microenvironment (TME) exerts mechanical and biochemical properties on tumor cells, modulates interstitial fluid pressure, and reduces blood vessel density within tumors. Although evidence has shown that the ECM may be tumor promoting, recent research has demonstrated that the stroma and ECM may restrain tumor growth. In addition, tumor metastases, the primary cause of patient mortality, have less stroma than primary tumors. A major regulator of the ECM are cancer-associated fibroblasts (CAFs), which dominate the TME in abundance.

CAFs are thought to arise predominantly from pancreatic stellate cells (PSCs) and bone-marrow derived mesenchymal stem cells. Their formation has been shown to be secondary to tumor signals. Several attempts have been made to target CAFs and the stroma; however, they have not been successful despite promising preclinical studies. For example, genetic depletion of alpha-smooth muscle actin (αSMA) myofibroblasts in the stroma resulted in undifferentiated and invasive tumors with diminished survival. In metastatic PDAC patients, treatment with a pegylated recombinant human hyaluronidase (PEGPH20) combined with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) did not improve progression-free or overall survival. Trials using hedgehog (Hh) pathway inhibitors in combination with gemcitabine showed that the addition of Hh inhibitors was not superior to gemcitabine alone, and one study was prematurely terminated as patients treated with the Hh inhibitor did worse than the control arm. Despite these failures, targeting and modifying CAFs and the ECM continues to remain a topic of interest due to the substantial roles they play in tumor development, growth, and metastasis.

The cross-regulated and interacting networks of ECM proteins are fundamental to tumor homeostasis and tumorigenic activity like growth and metastasis and must be further understood. This dynamic environment provides a reservoir for signaling molecules and prompts tumor cell activity via mechanical forces and biochemical signaling. This review covers the composition and general roles and regulation of the ECM in PDAC, key proteins in the ECM, and potential and ongoing targeting strategies.

ECM Overview

The ECM is a non-cellular component present in all tissue and provides the essential physical scaffolding, as well as biochemical and biomechanical cues to the surrounding cellular components. Consisting of water, proteins, and polysaccharides, the ECM composition adjusts based on the needs of the surrounding microenvironment. Most tissue require an ECM as an interstitial matrix in which the ECM is a 3-dimensional lattice supporting the surrounding cells of the stroma or a basement membrane in which the ECM is a matrix between epithelial and stromal layers of cells. Change in ECM architecture is a result of malignant cell transformation in many cancers, thus demonstrating the influence of biomechanical cues from the ECM.

Tumor stroma has often been portrayed as a contributor to the development of the disease and tumor progression. However, several recent preclinical and clinical studies have shown that stroma-depletion can lead to a more aggressive disease. In patients, we and others have found that increased stroma correlates with improved survival and that stroma content at solid organ metastases is decreased. Reduction of ECM through lysyl oxidase (LOX) inhibition in mouse models led to accelerated tumor growth.

Thus, the stroma and ECM play a dichotomous role in the TME as a tumor-promoting and tumor-inhibiting component, and selectively targeting the stroma and ECM may be the key. However, a more complete understanding of the stroma and the TME is necessary for this to succeed. The PDAC ECM is primarily composed of collagens, integrins, proteoglycans, glycoproteins, and proteases which all interact with tumor cells through a variety of mechanisms ( Figure 1 ). Among these, collagens are the most abundant component.

Collagens

The PDAC ECM contains combinations of type I, III, IV, V, and XV collagens. The interaction between collagen and the basement membrane proteins within the ECM plays an important role during malignant transformation. Increased desmoplasia is thought to contribute to disruption of the basement membrane leading to increased exposure of PDAC cells to interstitial collagens and reduction of basement membrane collagens. In PDAC, lower collagen I and IV is associated with undifferentiated PDAC tumors. Basement membrane proteins are suggested to be tumor-inhibiting by restricting the epithelial-to-mesenchymal transition (EMT), whereas interstitial collagens may promote tumor growth through other mechanisms. Preclinical studies have shown that collagen may contribute to therapy resistance by modulating signaling pathways. In patients, studies have found that imaging characteristics may be reflective of stroma content and patient outcome.

Collagens I, III, IV, and V

Collagen I is among the most abundant collagen in PDAC stroma and is generally suggested to be responsible for most of the desmoplastic reaction and has been associated with reduced survival in PDAC patients. However, when C-terminal prodomains of collagen I are cleaved by procollagen C-proteinase activity, collagen I may restrain tumor growth. In addition, the presence of collagen I in the TME does not appear to inhibit T-cell infiltration, further suggesting the stroma has roles beyond a physical barrier. Collagen III is the second most abundant collagen present in the PDAC ECM. Like collagen I, collagen III may suppress tumor growth when cleaved. In addition, the ratio of collagen III to collagen III peptide fragments may be predictive of improved patient survival. Collagen IV, a collagen commonly found in the interstitial space, is overexpressed and deposited in the stroma by PDAC cells. In vitro assays using α1(IV)-siRNA demonstrated that collagen IV silencing reduces tumor cell proliferation and migration and increases apoptosis. Lastly, the fibrillar collagen, collagen V, is often identified as PSC-derived in PDAC and can be blocked by inhibiting β1-integrin signaling. Genetic knock-down of collagen V in orthotopic mouse models demonstrated reduced tumor metastasis and angiogenesis.

Collagen Signaling

ECM collagens interact with signaling integrins expressed on the surface of PDAC cells. Collagens bind with the α- and β-subunits of integrins depending on the integrin specificity of the collagen subtype. Interstitial collagens I, IV, and V have a high affinity for integrin α2β1, and the interaction between collagen I or V with α2β1 promotes proliferation and migration of PDAC cells. Like integrin-mediated signaling, collagens also interact with the cell surface receptor discoidin receptor 1 (DDR-1), a tyrosine kinase overexpressed by PDAC cells. Active DDR-1 activates FAK-related protein tyrosine kinase (PYK2).

Collagen as Nutrients

Proliferating tumor cells require a constant supply of nutrients which are scarcely present in the dense desmoplastic tissue. Furthermore, the TME is generally hypoxic due to increased intra-tumoral oncotic pressure that decreases tissue perfusion. To adapt, PDAC cells may use large macropinosomes to non-specifically take up nutrients from the surrounding TME in bulk. In this way, PDAC cells are thought to actively scavenge the TME’s breakdown products and use collagen-derived proline as a primary source of energy in the absence of glucose ( Figure 1 ). Likewise, proline oxidase (PRODH1) is overexpressed in proline catabolizing PDAC cells.

Integrins, Proteoglycans, and Glycoproteins

In addition to collagen, the TME also contains integrins, proteoglycans, and glycoproteins. Integrins mediate the interactions between TME cell-types and ECM proteins like proteoglycans and glycoproteins. Both proteoglycans and glycoproteins undergo post-translational glycosylation which modulates their functions and conformation. Aberrant glycosylation, a hallmark of several cancers, modifies the behavior of proteoglycans and glycoproteins in the TME; therefore, it is expected that the two classes of proteins play several modified roles in the TME.

Integrins

Integrins are transmembrane cell-surface receptors that heterodimerize upon binding ECM glycoproteins like fibronectin (FN1) and vitronectin (VN), collagens, and laminin. These cell-surface receptors are the major cell-adhesion receptors that interact with the ECM. In addition to directly contacting the ECM, activated integrins recruit the adhesome to the cytosolic tail of the integrin, a complex assortment of signaling, scaffolding, and cytoskeletal proteins. Differentially expressed in several solid tumors including PDAC, integrin roles are multi-faceted and participate in the metastatic cascade. Integrin-to-ECM contact points serve as molecular clutches to propel tumor cells forward by converting actin-polymerization into traction force. In addition, by promoting the expression of matrix metalloproteinases (MMPs), integrins increase the proteolytic activity within the ECM and may facilitate the release of individual cancer cells or cell clusters from the TME. Integrin expression on cancer cells and endothelial cells has also been implicated in extravasation. In particular, PDAC zebrafish and mouse models demonstrated that the interaction between α5 integrin and neuropilin-2 facilitates the binding of cancer cells to the endothelium. Knockdown using lentiviral RNA-interference reduced cell adhesion, migration, and proliferation in vitro and vivo. In PDAC mouse models, the galectin-3 (GAL3) interaction with αvβ3 integrin may serve as an underlying mechanism of KRAS addiction and increase nutrient uptake via micropinocytosis. Altogether, PDAC has demonstrated overexpression of members of the integrin family like β1, β3, and β6 compared to normal pancreas.

Glycoproteins and Proteoglycans

The glycoprotein galectin-1 (GAL1) has been found to be upregulated in the PDAC TME, alongside other glycoproteins like periostin and fibulin and is lowly expressed in long-term (≥10 years) survivors of PDAC. Loss of GAL1 in murine models leads to reduced stromal activation and increased cytotoxic T-cell infiltration. FN1 and VN are thought to serve as scaffolding proteins in the PDAC TME and regulate cellular processes. FN1 enables tumor cells to infiltrate the basement membrane, stimulates their proliferation, and bridges the interactions between ECM collagens and integrins ( Figure 1 ). FN1 is also known to stimulate transforming growth factor-β (TGFβ) secretion, in turn promoting the activation of the stroma. Secreted protein acidic and rich in cysteine (SPARC) is another major glycoprotein in the PDAC stroma that modulates ECM organization by directly binding to collagens I, III, IV, and V. In addition, SPARC, expressed in the stroma from fibroblasts, regulates the interactions between integrins and ECM proteins by binding α5β1 focal adhesion sites. SPARC deficient mice demonstrated reduced collagen fibrillogenesis, and elevated metastasis.

The glycoprotein subclass, proteoglycans, often modulate the hydration level of the interstitial fluid, and in turn interstitial pressure, through its interactions with hyaluronic acid (HA). However, HA modulation of interstitial pressure is suggested to be dependent on the collagen-richness of the TME and may not occur in collagen-replete TMEs. The TME of PDAC overproduces an abundance of HA beginning at the pre-malignant intraepithelial neoplasia (PanIN) stage. When HA is enzymatically depleted in mouse models, the delivery of cytotoxic therapies is enhanced, likely due to a compromised ECM lacking HA.

Secretome Studies

PDAC secretome analyses aim to examine the surrounding PDAC environment to identify aberrant proteins or molecules that may be influence tumor progression. A meta-analysis of 20 PDAC secretome studies from cell lines and patient tissues found that proteins associated with extracellular exosomes, blood microparticles, membrane-bound, secretory lumen and cytoplasmic membrane-bound vesicles, were most commonly found. Notable proteins found among the secretome and proteome across 20 secretome studies and 35 proteome studies include TGFβ induced (TGFBI), vimentin, and fibronectin. Using 3D organotypic cell cultures, Biondani et al. demonstrated that incubating cells with increasing type I collagen promoted the secretion of pro-angiogenic and growth factors like epidermal growth factor (EGF), matrix metalloproteinase 9 (MMP9), and vascular endothelial growth factor (VEGF).

Regulation of the ECM

PSCs are thought to maintain the balance between ECM synthesis and degradation and serve as a cellular reservoir for vitamin A and lipids. In the presence of tumor cells, PSCs assume an “activated” state in which they excessively deposit ECM proteins; become elongated in shape; and demonstrate increased expression of αSMA, collagens, immune-modulating, and other tumor-promoting genes. The formation of CAFs from PSCs is thought to be mediated by the PDAC secretome, which is abundant in fibroblast growth factor 2 (FGF2), TGFβ, and the paracrine and autocrine signaling regulator, sonic hedgehog (Shh). Shh functions to attract and activate PSCs, as PSCs demonstrate enhanced migration towards Shh overexpressing PDAC cells. PSC activation through paracrine signaling has been shown to be inhibited with metformin, an activator of AMP-activated protein kinase (AMPK).

TGFβ may suppress tumor growth in the early stages of carcinogenesis by inhibiting the proliferation of epithelial cells. However, in late stages of carcinogenesis, TGFβ promotes ECM deposition and tumor progression. A potent activator of PSCs, TGFβ mediates the interaction between the TME and tumor cells by binding TGFβ cell surface receptors. In PDAC, TGFβ promotes the deposition of several ECM proteins including fibronectin and collagens. On the surface of tumor cells, TGFβ receptor bind TGFβ to regulate downstream Smad-mediated gene transcription. PDAC-secreted TGFβ1 and FGF2 then promote ECM deposition by PSCs, as well as a positive feedback loop whereby PSCs secrete additional TGFβ1 that bind to TGFβ1-receptors found on the surface of PSCs. Once activated, PSCs, also known as CAFs, further modulate the ECM through a variety of mechanisms.

Tissue stiffness has been shown to enhance tumor cell proliferation in models of breast cancer. Stiff ECM matrices modulate vimentin, E-cadherin (CDH1), and ECM MMP activity. Stiffening of the stroma is enhanced by collagen cross-linking carried out by LOX and tissue transglutaminase 2 (TG2) ( Figure 1 ). LOX expression is increased under hypoxic conditions and systematic neutralization of LOX results in reduced proliferation and improved survival in mouse models. On the other hand, TG2 secreted into the ECM promotes collagen I cross-linking and stimulates CAFs to produce additional collagen I. In pancreatic tissue, TG2 is mildly expressed unless malignancy is present. Similar to stiffness, increased collagen fiber thickness is associated with poor patient outcome. The additional cross-linked collagen and stiff ECM, prompted by TG2 and/or LOX, activates yes-associated protein (YAP) and the transcriptional coactivator with a PDZ-binding motif (TAZ) that enhances cell proliferation. It is suggested that the YAP/TAZ signaling is the central hub for the cellular response to external mechanical cues, highlighted by increased nuclear localization of YAP/TAZ in response to mechanical stiffness.

Hyaluronic Acid

The rationale for targeting the ECM as an adjunct to chemotherapy in PDAC relies on our understanding of the roles that ECM plays in promoting tumorigenesis. Early studies in mouse models showed that tumors with a high HA content had increased interstitial pressure that resulted in vascular collapse and diminished tumor perfusion. Treating these mice with a hyaluronidase inhibitor reversed these effects, creating an amenable environment for intra-tumoral drug delivery. Since HA contributed to intra-tumoral pressure which in-turn affected drug delivery, the hypothesis was that targeting HA would improve drug delivery and efficacy. In SWOG S1313 (NCT01959139), PEGPH20 was evaluated in combination with mFOLFIRINOX and in the HALO trial (NCT02715804), in combination with nab-paclitaxel plus gemcitabine ( Table 1 ). Unfortunately, some patients experienced strong adverse reactions to PEGPH20 and those who tolerated it did not have an improvement in overall survival.

Hedgehog Pathway

Treating mice with Shh inhibitors in addition to chemotherapy improved tumor microvascular density and survival. The addition of Shh inhibitors to either FOLFIRINOX or gemcitabine in clinical trials failed to improve overall survival and, in some cases, was associated with a worse outcome ( Table 1 ). These studies were done prior to our understanding of CAF heterogeneity, and recent work has been done to further elucidate the underlying biology responsible for the discrepancy in clinical findings. Recent studies suggest that blocking the Shh signaling pathway may shift the stroma CAF populations from myofibroblast-CAFs (myCAFs) to inflammatory CAFs (iCAFs) and promote an immunosuppressive TME.

Rho Kinase Inhibitors

Rho kinase (ROCK) inhibitors alter PDAC cell cytoskeletal contractility and CAF contractility and may enable more favorable drug delivery in PDAC as well as inhibit PDAC metastasis. ROCK inhibition resulted in a disorganized ECM that blunted PDAC migration and invasion in vitro. In vivo models including both subcutaneous and intrasplenic injection found that administering ROCK-inhibitors prior to chemotherapy resulted in increased primary tumor response to chemotherapy and helped prevent the growth and establishment of liver metastases. A phase 1 study using a kinase inhibitor, AT13148, with anti-ROCKI/II activity was carried out in patients with metastatic solid tumors, but did not proceed further due to toxicity ( Table 1 ).

Vitamin D

Vitamin D halts the secretion of collagen in several cell types, possibly by disrupting TGF-β signaling. The vitamin D receptor (VDR) has been shown to regulate transcription of PSCs and CAFs. Treatment with VDR ligand, calcipotriol, reprograms the stroma, decreases inflammation and improves response to gemcitabine. Other studies have shown that while calcipotriol decreases CAF migration and inflammation, it also may negatively affect T cell effector functions. Several studies of paricalcitol, a vitamin D analogue, in combination with chemotherapies and immunotherapies are ongoing ( Table 1 ).

TGFβ

Preclinical experimental data has suggested that blocking TGFβ-mediated signaling likely enhances antitumor effects in solid tumors. Further, PDAC is often characterized by high TGFβ expression levels. Several clinical trials have attempted to target TGFβ in a variety of cancers, but no TGFβ-targeting inhibitor has been approved for use. There is currently at least one ongoing clinical trial targeting TGFβ in PDAC ( Table 1 ) that is investigating the pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR439459 alone and in combination with cemiplimab. SAR439459 is a pan-TGFβ neutralizing antibody that targets the three TGFβ isoforms (TGFβ1, 2 and 3) and their interaction with type II TGFβ cell surface receptors.

Concluding Remarks

The ECM plays an important role in PDAC tumor growth, metastasis, and therapy resistance. Accumulating preclinical studies with patient-derived specimens indicate that targeting the dense desmoplastic ECM proteins of PDAC may provide promising clinically useful therapies. In clinical practice, we have yet to successfully target the ECM in a way that improves overall survival. The clinical shortcomings of once promising therapies are a humble reminder of the underlying complexity of tumor biology. Learning from these failures and developing a deeper understanding of the fundamental biology allows researchers to identify further vulnerabilities that should be considered when developing treatments. Tumor and CAF subtypes have been identified that were previously not known and will likely improve the outcome of ECM modulating studies if performed using reproducible subtyping methods and tailored targeting techniques. Recent advances foster hope that ECM-modulating therapies are likely to become a crucial part of the toolkit for oncologists in the next few decades.

Author Contributions

All authors listed have made a substantial direct and intellectual contribution to the work and approved it for publication.

Funding

This work was financially supported by the National Cancer Institute of the National Institutes of Health under the award numbers R01-CA199064 (JY) and T32-CA244125 (JK, VP).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 133

  1. 1.

    Rahib L Smith BD Aizenberg R Rosenzweig AB Fleshman JM Matrisian LM. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res (2014 ) 74:2913

    Not in our library10.1158/0008-5472.can-14-0155

  2. 2.

    Siegel RL Miller KD Fuchs HE Jemal A. Cancer Statistics, 2021. CA: A Cancer J Clin (2021 ) 71:7–33

    Not in our library10.3322/caac.21654

  3. 3.

    Balaban EP Mangu PB Khorana AA Shah MA Mukherjee S Crane CH. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2016 ) 34:2654–68

    Not in our library10.1200/jco.2016.67.5561

  4. 4.

    Conroy T Desseigne F Ychou M Bouché O Guimbaud R Bécouarn Y. FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer. New Engl J Med (2011 ) 364:1817–25

    Not in our library10.1056/nejmoa1011923

  5. 5.

    Von Hoff DD Ervin T Arena FP Chiorean EG Infante J Moore M. Increased Survival in Pancreatic Cancer With Nab-Paclitaxel Plus Gemcitabine. New Engl J Med (2013 ) 369:1691–703

    Not in our library10.1056/nejmoa1304369

  6. 6.

    Golan T Hammel P Reni M Van Cutsem E Macarulla T Hall MJ. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. New Engl J Med (2019 ) 381:317–27

    Not in our library10.1056/nejmoa1903387

  7. 7.

    Pandol S Edderkaoui M Gukovsky I Lugea A Gukovskaya A. Desmoplasia of Pancreatic Ductal Adenocarcinoma. Clin Gastroenterol Hepatol (2009 ) 7:S44–7

    Not in our library10.1016/j.cgh.2009.07.039

  8. 8.

    Jacobetz MA Chan DS Neesse A Bapiro TE Cook N Frese KK. Hyaluronan Impairs Vascular Function and Drug Delivery in a Mouse Model of Pancreatic Cancer. Gut (2013 ) 62:112–20

    Not in our library10.1136/gutjnl-2012-302529

  9. 9.

    Olive KP Jacobetz MA Davidson CJ Gopinathan A Mcintyre D Honess D. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science (2009 ) 324:1457–61

    Not in our library10.1126/science.1171362

  10. 10.

    Elahi-Gedwillo KY Carlson M Zettervall J Provenzano PP. Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. Cancer Res (2019 ) 79:372–86

    Not in our library10.1158/0008-5472.can-18-1334

  11. 11.

    Lee JJ Perera RM Wang H Wu D-C Liu XS Han S. Stromal Response to Hedgehog Signaling Restrains Pancreatic Cancer Progression. Proc Natl Acad Sci USA (2014 ) 111:E3091–100

    Not in our library10.1073/pnas.1411679111

  12. 12.

    Whittle MC Izeradjene K Rani PG Feng L Carlson MA Delgiorno KE. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Cell (2015 ) 161:1345–60

    Not in our library10.1016/j.cell.2015.04.048

  13. 13.

    Jiang H Torphy RJ Steiger K Hongo H Ritchie AJ Kriegsmann M. Pancreatic Ductal Adenocarcinoma Progression Is Restrained by Stromal Matrix. J Clin Invest (2020 ) 130:4704–9

    Not in our library10.1172/jci136760

  14. 14.

    Torphy RJ Wang Z True-Yasaki A Volmar KE Rashid N Yeh B. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precis Oncol (2018 ) 2018:1–12

    Not in our library10.1200/po.17.00121

  15. 15.
    A framework for advancing our understanding of cancer-associated fibroblasts · 2020
    No notice
  16. 16.
    Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer · 2017
    No notice
  17. 17.

    Provenzano PP Cuevas C Chang AE Goel VK Von Hoff DD Hingorani SR. Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma. Cancer Cell (2012 ) 21:418–29

    Not in our library10.1016/j.ccr.2012.01.007

  18. 18.

    Özdemir BC Pentcheva-Hoang T Carstens JL Zheng X Wu C-C Simpson TR. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer With Reduced Survival. Cancer Cell (2014 ) 25:719–34

    Not in our library10.1016/j.ccr.2014.04.005

  19. 19.

    Ramanathan RK Mcdonough SL Philip PA Hingorani SR Lacy J Kortmansky JS. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. J Clin Oncol (2019 ) 37:1062–9

    Not in our library10.1200/jco.18.01295

  20. 20.

    Kim EJ Sahai V Abel EV Griffith KA Greenson JK Takebe N. Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma. Clin Cancer Res (2014 ) 20:5937–45

    Not in our library10.1158/1078-0432.ccr-14-1269

  21. 21.
    Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma · 2019
    No notice
  22. 22.

    Catenacci DVT Junttila MR Karrison T Bahary N Horiba MN Nattam SR. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol (2015 ) 33:4284–92

    Not in our library10.1200/jco.2015.62.8719

  23. 23.

    Neesse A Bauer CA Öhlund D Lauth M Buchholz M Michl P. Stromal Biology and Therapy in Pancreatic Cancer: Ready for Clinical Translation? Gut (2019 ) 68:159

    Not in our library10.1136/gutjnl-2018-316451

  24. 24.

    Humphrey JD Dufresne ER Schwartz MA. Mechanotransduction and Extracellular Matrix Homeostasis. Nat Rev Mol (2014 ) 15:802–12

    Not in our library10.1038/nrm3896

  25. 25.

    Pickup MW Mouw JK Weaver VM. The Extracellular Matrix Modulates the Hallmarks of Cancer. EMBO Rep (2014 ) 15:1243–53

    Not in our library10.15252/embr.201439246

  26. 26.

    Ligorio M Sil S Malagon-Lopez J Nieman LT Misale S Di Pilato M. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell (2019 ) 178:160–175.e127

    Not in our library10.1016/j.cell.2019.05.012

  27. 27.

    Xu Q Wang Z Chen X Duan W Lei J Zong L. Stromal-Derived Factor-1α/CXCL12-CXCR4 Chemotactic Pathway Promotes Perineural Invasion in Pancreatic Cancer. Oncotarget (2015 ) 6:4717–32

    Not in our library10.18632/oncotarget.3069

  28. 28.

    Wu XZ Chen D Xie GR. Extracellular Matrix Remodeling in Hepatocellular Carcinoma: Effects of Soil on Seed? Med Hypotheses (2006 ) 66:1115–20

    Not in our library10.1016/j.mehy.2005.12.043

  29. 29.

    Parker AL Cox TR. The Role of the ECM in Lung Cancer Dormancy and Outgrowth. Front Oncol (2020 ) 10:1766–6

    Not in our library10.3389/fonc.2020.01766

  30. 30.

    Ko AH Loconte N Tempero MA Walker EJ Kate Kelley R Lewis S. A Phase I Study of FOLFIRINOX Plus IPI-926, A Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas (2016 ) 45:370–5

    Not in our library10.1097/mpa.0000000000000458

  31. 31.

    Rhim AD Oberstein PE Thomas DH Mirek ET Palermo CF Sastra SA. Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell (2014 ) 25:735–47

    Not in our library10.1016/j.ccr.2014.04.021

  32. 32.

    Tian C Clauser KR Öhlund D Rickelt S Huang Y Gupta M. Proteomic Analyses of ECM During Pancreatic Ductal Adenocarcinoma Progression Reveal Different Contributions by Tumor and Stromal Cells. Proc Natl Acad Sci USA (2019 ) 116:19609–18

    Not in our library10.1073/pnas.1908626116

  33. 33.
    The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship · 2018
    No notice
  34. 34.

    Van Agtmael T Bruckner-Tuderman L. Basement Membranes and Human Disease. Cell Tissue Res (2009 ) 339:167

    Not in our library10.1007/s00441-009-0866-y

  35. 35.

    Karsdal MA Nielsen SH Leeming DJ Langholm LL Nielsen MJ Manon-Jensen T. The Good and the Bad Collagens of Fibrosis – Their Role in Signaling and Organ Function. Advanced Drug Delivery Rev (2017 ) 121:43–56

    Not in our library10.1016/j.addr.2017.07.014

  36. 36.
    The role of collagen in cancer: from bench to bedside · 2019
    No notice
  37. 37.
    Predicting postoperative peritoneal metastasis in gastric cancer with serosal invasion using a collagen nomogram · 2021
    No notice
  38. 38.

    Wegner CS Gaustad J-V Andersen LMK Simonsen TG Rofstad EK. Diffusion-Weighted and Dynamic Contrast-Enhanced MRI of Pancreatic Adenocarcinoma Xenografts: Associations With Tumor Differentiation and Collagen Content. J Transl Med (2016 ) 14:161–1

    Not in our library10.1186/s12967-016-0920-y

  39. 39.

    Senthebane DA Jonker T Rowe A Thomford NE Munro D Dandara C. The Role of Tumor Microenvironment in Chemoresistance: 3d Extracellular Matrices as Accomplices. Int J Mol Sci (2018 ) 19:2861

    Not in our library10.3390/ijms19102861

  40. 40.

    Sterzyńska K Klejewski A Wojtowicz K Świerczewska M Nowacka M Kaźmierczak D. Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development. Int J Mol Sci (2018 ) 20:54

    Not in our library10.3390/ijms20010054

  41. 41.

    Jakubzig B Baltes F Henze S Schlesinger M Bendas G. Mechanisms of Matrix-Induced Chemoresistance of Breast Cancer Cells-Deciphering Novel Potential Targets for a Cell Sensitization. Cancers (2018 ) 10:495

    Not in our library10.3390/cancers10120495

  42. 42.

    Koay EJ Lee Y Cristini V Lowengrub JS Kang YA Lucas FAS. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res (2018 ) 24:5883–94

    Not in our library10.1158/1078-0432.ccr-17-3668

  43. 43.

    Imamura T Iguchi H Manabe T Ohshio G Yoshimura T Wang Z-H. Quantitative Analysis of Collagen and Collagen Subtypes I, III, and V in Human Pancreatic Cancer, Tumor-Associated Chronic Pancreatitis, and Alcoholic Chronic Pancreatitis. Pancreas (1995 ) 11:357–64

    Not in our library10.1097/00006676-199511000-00007

  44. 44.

    Mollenhauer J Roether I Kern HF. Distribution of Extracellular Matrix Proteins in Pancreatic Ductal Adenocarcinoma and Its Influence on Tumor Cell Proliferation In Vitro. Pancreas (1987 ) 2:14–24

    Not in our library10.1097/00006676-198701000-00003

  45. 45.

    Whatcott CJ Diep CH Jiang P Watanabe A Lobello J Sima C. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Clin Cancer Res (2015 ) 21:3561–8

    Not in our library10.1158/1078-0432.ccr-14-1051

  46. 46.
    Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells · 2021
    Not checked
  47. 47.

    Madsen CD. Pancreatic Cancer Is Suppressed by Fibroblast-Derived Collagen I. Cancer Cell (2021 ) 39:451–3

    Not in our library10.1016/j.ccell.2021.02.017

  48. 48.
    Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer · 2017
    No notice
  49. 49.

    Willumsen N Ali SM Leitzel K Drabick JJ Yee N Polimera HV. Collagen Fragments Quantified in Serum as Measures of Desmoplasia Associate With Survival Outcome in Patients With Advanced Pancreatic Cancer. Sci Rep (2019 ) 9:19761–1

    Not in our library10.1038/s41598-019-56268-3

  50. 50.

    Ohlund D Lundin C Ardnor B Oman M Naredi P Sund M. Type IV Collagen Is a Tumour Stroma-Derived Biomarker for Pancreas Cancer. Br J Cancer (2009 ) 101:91–7

    Not in our library10.1038/sj.bjc.6605107

  51. 51.
    Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop · 2013
    No notice
  52. 52.

    Berchtold S Grünwald B Krüger A Reithmeier A Hähl T Cheng T. Collagen Type V Promotes the Malignant Phenotype of Pancreatic Ductal Adenocarcinoma. Cancer Lett (2015 ) 356:721–32

    Not in our library10.1016/j.canlet.2014.10.020

  53. 53.

    Tulla M Pentikäinen OT Viitasalo T Käpylä J Impola U Nykvist P. Selective Binding of Collagen Subtypes by Integrin A1l, A2l, and A10l Domains *. J Biol Chem (2001 ) 276:48206–12

    Not in our library10.1074/jbc.m104058200

  54. 54.

    Grzesiak JJ Bouvet M. Determination of the Ligand-Binding Specificities of the α2β1 and α1β1 Integrins in a Novel 3-Dimensional In Vitro Model of Pancreatic Cancer. Pancreas (2007 ) 34:220–8

    Not in our library10.1097/01.mpa.0000250129.64650.f6

  55. 55.

    Armstrong T Packham G Murphy LB Bateman AC Conti JA Fine DR. Type I Collagen Promotes the Malignant Phenotype of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res (2004 ) 10:7427

    Not in our library10.1158/1078-0432.ccr-03-0825

  56. 56.

    Ruggiero F Comte J Cabañas C Garrone R. Structural Requirements for Alpha 1 Beta 1 and Alpha 2 Beta 1 Integrin Mediated Cell Adhesion to Collagen V. J Cell Sci (1996 ) 109(Pt 7):1865–74

    Not in our library10.1242/jcs.109.7.1865

  57. 57.

    Valiathan RR Marco M Leitinger B Kleer CG Fridman R. Discoidin Domain Receptor Tyrosine Kinases: New Players in Cancer Progression. Cancer metastasis Rev (2012 ) 31:295–321

    Not in our library10.1007/s10555-012-9346-z

  58. 58.

    Commisso C Davidson SM Soydaner-Azeloglu RG Parker SJ Kamphorst JJ Hackett S. Macropinocytosis of Protein Is an Amino Acid Supply Route in Ras-Transformed Cells. Nature (2013 ) 497:633–7

    Not in our library10.1038/nature12138

  59. 59.

    Bar-Sagi D Feramisco JR. Induction of Membrane Ruffling and Fluid-Phase Pinocytosis in Quiescent Fibroblasts by Ras Proteins. Science (1986 ) 233:1061

    Not in our library10.1126/science.3090687

  60. 60.

    Davidson SM Jonas O Keibler MA Hou HW Luengo A Mayers JR. Direct Evidence for Cancer-Cell-Autonomous Extracellular Protein Catabolism in Pancreatic Tumors. Nat Med (2017 ) 23:235–41

    Not in our library10.1038/nm.4256

  61. 61.

    Kamphorst JJ Nofal M Commisso C Hackett SR Lu W Grabocka E. Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein. Cancer Res (2015 ) 75:544–53

    Not in our library10.1158/0008-5472.can-14-2211

  62. 62.
    Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions · 2017
    No notice
  63. 63.

    Pan S Brentnall TA Chen R. Glycoproteins and Glycoproteomics in Pancreatic Cancer. World J Gastroenterol (2016 ) 22:9288–99

    Not in our library10.3748/wjg.v22.i42.9288

  64. 64.

    Hamidi H Ivaska J. Every Step of the Way: Integrins in Cancer Progression and Metastasis. Nat Rev Cancer (2018 ) 18:533–48

    Not in our library10.1038/s41568-018-0038-z

  65. 65.

    Horton ER Byron A Askari JA Ng DHJ Millon-Frémillon A Robertson J. Definition of a Consensus Integrin Adhesome and its Dynamics During Adhesion Complex Assembly and Disassembly. Nat Cell Biol (2015 ) 17:1577–87

    Not in our library10.1038/ncb3257

  66. 66.
    The integrin adhesome network at a glance · 2016
    No notice
  67. 67.

    Zaidel-Bar R Itzkovitz S Ma’ayan A Iyengar R Geiger B. Functional Atlas of the Integrin Adhesome. Nat Cell Biol (2007 ) 9:858–67

    Not in our library10.1038/ncb0807-858

  68. 68.

    Ahmed N Pansino F Clyde R Murthi P Quinn MA Rice GE. Overexpression of αvβ6 Integrin in Serous Epithelial Ovarian Cancer Regulates Extracellular Matrix Degradation via the Plasminogen Activation Cascade. Carcinogenesis (2002 ) 23:237–44

    Not in our library10.1093/carcin/23.2.237

  69. 69.

    Baum O Hlushchuk R Forster A Greiner R Clézardin P Zhao Y. Increased Invasive Potential and Up-Regulation of MMP-2 in MDA-MB-231 Breast Cancer Cells Expressing the β3 Integrin Subunit. Int J Oncol (2007 ) 30:325–32

    Not in our library10.3892/ijo.30.2.325

  70. 70.

    Sipos B Hahn D Carceller A Piulats J Hedderich J Kalthoff H. Immunohistochemical Screening for β6-Integrin Subunit Expression in Adenocarcinomas Using a Novel Monoclonal Antibody Reveals Strong Up-Regulation in Pancreatic Ductal Adenocarcinomas In Vivo and In Vitro. Histopathology (2004 ) 45:226–36

    Not in our library10.1111/j.1365-2559.2004.01919.x

  71. 71.

    Gardel ML Sabass B Ji L Danuser G Schwarz US Waterman CM. Traction Stress in Focal Adhesions Correlates Biphasically With Actin Retrograde Flow Speed. J Cell Biol (2008 ) 183:999–1005

    Not in our library10.1083/jcb.200810060

  72. 72.

    Yue J Zhang K Chen J. Role of Integrins in Regulating Proteases to Mediate Extracellular Matrix Remodeling. Cancer Microenviron Off J Int Cancer Microenviron Soc (2012 ) 5:275–83

    Not in our library10.1007/s12307-012-0101-3

  73. 73.

    Munshi HG Stack MS. Reciprocal Interactions Between Adhesion Receptor Signaling and MMP Regulation. Cancer Metastasis Rev (2006 ) 25:45–56

    Not in our library10.1007/s10555-006-7888-7

  74. 74.
    Endothelial destabilization by angiopoietin-2 via integrin β1 activation · 2015
    No notice
  75. 75.

    Cao Y Hoeppner LH Bach S E G Guo Y Wang E. Neuropilin-2 Promotes Extravasation and Metastasis by Interacting With Endothelial α5 Integrin. Cancer Res (2013 ) 73:4579–90

    Not in our library10.1158/0008-5472.can-13-0529

  76. 76.

    Grzesiak JJ Tran Cao HS Burton DW Kaushal S Vargas F Clopton P. Knockdown of the β(1) Integrin Subunit Reduces Primary Tumor Growth and Inhibits Pancreatic Cancer Metastasis. Int J Cancer (2011 ) 129:2905–15

    Not in our library10.1002/ijc.25942

  77. 77.

    Seguin L Camargo MF Wettersten HI Kato S Desgrosellier JS Von Schalscha T. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discovery (2017 ) 7:1464–79

    Not in our library10.1158/2159-8290.cd-17-0539

  78. 78.

    Pan S Chen R Tamura Y Crispin DA Lai LA May DH. Quantitative Glycoproteomics Analysis Reveals Changes in N-Glycosylation Level Associated With Pancreatic Ductal Adenocarcinoma. J Proteome Res (2014 ) 13:1293–306

    Not in our library10.1021/pr4010184

  79. 79.

    Chen R Pan S Ottenhof NA De Wilde RF Wolfgang CL Lane Z. Stromal Galectin-1 Expression Is Associated With Long-Term Survival in Resectable Pancreatic Ductal Adenocarcinoma. Cancer Biol Ther (2012 ) 13:899–907

    Not in our library10.4161/cbt.20842

  80. 80.

    Chen R Dawson DW Pan S Ottenhof NA De Wilde RF Wolfgang CL. Proteins Associated With Pancreatic Cancer Survival in Patients With Resectable Pancreatic Ductal Adenocarcinoma. Lab investigation; J Tech Methods Pathol (2015 ) 95:43–55

    Not in our library10.1038/labinvest.2014.128

  81. 81.

    Orozco CA Martinez-Bosch N Guerrero PE Vinaixa J Dalotto-Moreno T Iglesias M. Targeting Galectin-1 Inhibits Pancreatic Cancer Progression by Modulating Tumor-Stroma Crosstalk. Proc Natl Acad Sci USA (2018 ) 115:E3769–78

    Not in our library10.1073/pnas.1722434115

  82. 82.
    Plasma and cellular fibronectin: distinct and independent functions during tissue repair · 2011
    No notice
  83. 83.

    Löhr M Trautmann B Göttler M Peters S Zauner I Maillet B. Human Ductal Adenocarcinomas of the Pancreas Express Extracellular Matrix Proteins. Br J Cancer (1994 ) 69:144–51

    Not in our library10.1038/bjc.1994.24

  84. 84.

    Giancotti FG Ruoslahti E. Integrin Signaling. Science (1999 ) 285:1028

    Not in our library10.1126/science.285.5430.1028

  85. 85.

    Zeltz C Orgel J Gullberg D. Molecular Composition and Function of Integrin-Based Collagen Glues—Introducing COLINBRIs. Biochim Biophys Acta (BBA) - Gen Subj (2014 ) 1840:2533–48

    Not in our library10.1016/j.bbagen.2013.12.022

  86. 86.

    Miyamoto H Murakami T Tsuchida K Sugino H Miyake H Tashiro S. Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins. Pancreas (2004 ) 28:38–44

    Not in our library10.1097/00006676-200401000-00006

  87. 87.

    Dallas SL Sivakumar P Jones CJP Chen Q Peters DM Mosher DF. Fibronectin Regulates Latent Transforming Growth Factor-β (Tgfβ) by Controlling Matrix Assembly of Latent Tgfβ-Binding Protein-1 *. J Biol Chem (2005 ) 280:18871–80

    Not in our library10.1074/jbc.m410762200

  88. 88.

    Arnold SA Rivera LB Miller AF Carbon JG Dineen SP Xie Y. Lack of Host SPARC Enhances Vascular Function and Tumor Spread in an Orthotopic Murine Model of Pancreatic Carcinoma. Dis Models Mech (2010 ) 3:57–72

    Not in our library10.1242/dmm.003228

  89. 89.

    Egeblad M Rasch MG Weaver VM. Dynamic Interplay Between the Collagen Scaffold and Tumor Evolution. Curr Opin Cell Biol (2010 ) 22:697–706

    Not in our library10.1016/j.ceb.2010.08.015

  90. 90.

    Nie J Chang B Traktuev DO Sun J March K Chan L. IFATS Collection: Combinatorial Peptides Identify Alpha5beta1 Integrin as a Receptor for the Matricellular Protein SPARC on Adipose Stromal Cells. Stem Cells (Dayton Ohio) (2008 ) 26:2735–45

    Not in our library10.1634/stemcells.2008-0212

  91. 91.

    Fraser JRE Laurent TC Laurent UBG. Hyaluronan: Its Nature, Distribution, Functions and Turnover. J Internal Med (1997 ) 242:27–33

    Not in our library10.1046/j.1365-2796.1997.00170.x

  92. 92.

    Chauhan VP Martin JD Liu H Lacorre DA Jain SR Kozin SV. Angiotensin Inhibition Enhances Drug Delivery and Potentiates Chemotherapy by Decompressing Tumour Blood Vessels. Nat Commun (2013 ) 4:2516–6

    Not in our library10.1038/ncomms3516

  93. 93.

    Thompson CB Shepard HM Connor PM Kadhim S Jiang P Osgood RJ. Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models. Mol Cancer Ther (2010 ) 9:3052

    Not in our library10.1158/1535-7163.mct-10-0470

  94. 94.

    De Oliveira G Freire PP Cury SS De Moraes D Oliveira JS Dal-Pai-Silva M. An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma. Cancers (2020 ) 12:716

    Not in our library10.3390/cancers12030716

  95. 95.

    Biondani G Zeeberg K Greco MR Cannone S Dando I Dalla Pozza E. Extracellular Matrix Composition Modulates PDAC Parenchymal and Stem Cell Plasticity and Behavior Through the Secretome. FEBS J (2018 ) 285:2104–24

    Not in our library10.1111/febs.14471

  96. 96.
    Pancreatic stellate cells: a starring role in normal and diseased pancreas · 2012
    No notice
  97. 97.

    Bachem MG Schneider E Groß H Weidenbach H Schmid RM Menke A. Identification, Culture, and Characterization of Pancreatic Stellate Cells in Rats and Humans. Gastroenterology (1998 ) 115:421–32

    Not in our library10.1016/s0016-5085(98)70209-4

  98. 98.

    Bailey JM Swanson BJ Hamada T Eggers JP Singh PK Caffery T. Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer. Clin Cancer Res (2008 ) 14:5995–6004

    Not in our library10.1158/1078-0432.ccr-08-0291

  99. 99.

    Li X Wang Z Ma Q Xu Q Liu H Duan W. Sonic Hedgehog Paracrine Signaling Activates Stromal Cells to Promote Perineural Invasion in Pancreatic Cancer. Clin Cancer Res (2014 ) 20:4326

    Not in our library10.1158/1078-0432.ccr-13-3426

  100. 100.

    Duan W Chen K Jiang Z Chen X Sun L Li J. Desmoplasia Suppression by Metformin-Mediated AMPK Activation Inhibits Pancreatic Cancer Progression. Cancer Lett (2017 ) 385:225–33

    Not in our library10.1016/j.canlet.2016.10.019

  101. 101.
    TGF-β in pancreatic cancer initiation and progression: two sides of the same coin · 2017
    Not checked
  102. 102.

    Kato Y Inoue H Yoshioka U Fujiyama Y Bamba T. Effects of Transforming Growth Factor α1, Interleukin-1β, Tumor Necrosis Factor α and Platelet-Derived Growth Factor on the Collagen Synthesis and the Proliferation of Periacinal Fibroblastoid Cells Isolated and Cultured From Rat Pancreatic Acini. Pathophysiology (1996 ) 3:175–9

    Not in our library10.1016/0928-4680(96)00012-0

  103. 103.

    Shany S Sigal-Batikoff INA Lamprecht S. Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-Purposes With TGF-β/SMAD Signaling. Anticancer Res (2016 ) 36:6225

    Not in our library10.21873/anticanres.11216

  104. 104.

    Paszek MJ Zahir N Johnson KR Lakins JN Rozenberg GI Gefen A. Tensional Homeostasis and the Malignant Phenotype. Cancer Cell (2005 ) 8:241–54

    Not in our library10.1016/j.ccr.2005.08.010

  105. 105.
    Matrix stiffness induces epithelial–mesenchymal transition and promotes chemoresistance in pancreatic cancer cells · 2017
    No notice
  106. 106.

    Haage A Schneider IC. Cellular Contractility and Extracellular Matrix Stiffness Regulate Matrix Metalloproteinase Activity in Pancreatic Cancer Cells. FASEB J (2014 ) 28:3589–99

    Not in our library10.1096/fj.13-245613

  107. 107.

    Cox TR Bird D Baker A-M Barker HE Ho MWY Lang G. LOX-Mediated Collagen Crosslinking Is Responsible for Fibrosis-Enhanced Metastasis. Cancer Res (2013 ) 73:1721–32

    Not in our library10.1158/0008-5472.can-12-2233

  108. 108.

    Lee J Condello S Yakubov B Emerson R Caperell-Grant A Hitomi K. Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression. Clin Cancer Res (2015 ) 21:4482–93

    Not in our library10.1158/1078-0432.ccr-15-0226

  109. 109.

    Verderio EAM Johnson T Griffin M. Tissue Transglutaminase in Normal and Abnormal Wound Healing: Review Article. Amino Acids (2004 ) 26:387–404

    Not in our library10.1007/s00726-004-0094-4

  110. 110.

    Laklai H Miroshnikova YA Pickup MW Collisson EA Kim GE Barrett AS. Genotype Tunes Pancreatic Ductal Adenocarcinoma Tissue Tension to Induce Matricellular Fibrosis and Tumor Progression. Nat Med (2016 ) 22:497–505

    Not in our library10.1038/nm.4082

  111. 111.

    Dupont S Morsut L Aragona M Enzo E Giulitti S Cordenonsi M. Role of YAP/TAZ in Mechanotransduction. Nature (2011 ) 474:179–83

    Not in our library10.1038/nature10137

  112. 112.

    Piccolo S Dupont S Cordenonsi M. The Biology of YAP/TAZ: Hippo Signaling and Beyond. Physiol Rev (2014 ) 94:1287–312

    Not in our library10.1152/physrev.00005.2014

  113. 113.

    Gruber R Panayiotou R Nye E Spencer-Dene B Stamp G Behrens A. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-Regulation of JAK-STAT3 Signaling. Gastroenterology (2016 ) 151:526–39

    Not in our library10.1053/j.gastro.2016.05.006

  114. 114.

    Li X Shepard HM Cowell JA Zhao C Osgood RJ Rosengren S. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression. Clin Cancer Res (2018 ) 24:4798–807

    Not in our library10.1158/1078-0432.ccr-17-3284

  115. 115.

    Van Cutsem E Tempero MA Sigal D Oh D-Y Fazio N Macarulla T. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol (2020 ) 38:3185–94

    Not in our library10.1200/jco.20.00590

  116. 116.

    Steele NG Biffi G Kemp SB Zhang Y Drouillard D Syu L. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Clin Cancer Res (2021 ) 27:2023

    Not in our library10.1158/1078-0432.ccr-20-3715

  117. 117.

    Vennin C Chin VT Warren SC Lucas MC Herrmann D Magenau A. Transient Tissue Priming via ROCK Inhibition Uncouples Pancreatic Cancer Progression, Sensitivity to Chemotherapy, and Metastasis. Sci Transl Med (2017 ) 9:eaai8504

    Not in our library10.1126/scitranslmed.aai8504

  118. 118.

    Rath N Munro J Cutiongco MF Jagiełło A Gadegaard N Mcgarry L. Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. Cancer Res (2018 ) 78:3321–36

    Not in our library10.1158/0008-5472.can-17-1339

  119. 119.

    Whatcott CJ Ng S Barrett MT Hostetter G Von Hoff DD Han H. Inhibition of ROCK1 Kinase Modulates Both Tumor Cells and Stromal Fibroblasts in Pancreatic Cancer. PloS One (2017 ) 12:e0183871–e0183871

    Not in our library10.1371/journal.pone.0183871

  120. 120.

    Vennin C Rath N Pajic M Olson MF Timpson P. Targeting ROCK Activity to Disrupt and Prime Pancreatic Cancer for Chemotherapy. Small GTPases (2020 ) 11:45–52

    Not in our library10.1080/21541248.2017.1345712

  121. 121.

    Mcleod R Kumar R Papadatos-Pastos D Mateo J Brown JS Garces AHI. First-In-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients With Solid Tumors. Clin Cancer Res (2020 ) 26:4777

    Not in our library10.1158/1078-0432.ccr-20-0700

  122. 122.

    Artaza JN Norris KC. Vitamin D Reduces the Expression of Collagen and Key Profibrotic Factors by Inducing an Antifibrotic Phenotype in Mesenchymal Multipotent Cells. J Endocrinol (2009 ) 200:207–21

    Not in our library10.1677/joe-08-0241

  123. 123.

    Sherman MH Yu RT Engle DD Ding N Atkins AR Tiriac H. Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy. Cell (2014 ) 159:80–93

    Not in our library10.1016/j.cell.2014.08.007

  124. 124.

    Porter RL Magnus NKC Thapar V Morris R Szabolcs A Neyaz A. Epithelial to Mesenchymal Plasticity and Differential Response to Therapies in Pancreatic Ductal Adenocarcinoma. Proc Natl Acad Sci (2019 ) 116:26835

    Not in our library10.1073/pnas.1914915116

  125. 125.

    Cheng H Lu C Tang R Pan Y Bao S Qiu Y. Ellagic Acid Inhibits the Proliferation of Human Pancreatic Carcinoma PANC-1 Cells In Vitro and In Vivo. Oncotarget (2017 ) 8:12301–10

    Not in our library10.18632/oncotarget.14811

  126. 126.

    Gorchs L Ahmed S Mayer C Knauf A Fernández Moro C Svensson M. The Vitamin D Analogue Calcipotriol Promotes an Anti-Tumorigenic Phenotype of Human Pancreatic CAFs But Reduces T Cell Mediated Immunity. Sci Rep (2020 ) 10:17444

    Not in our library10.1038/s41598-020-74368-3

  127. 127.

    Ciardiello D Elez E Tabernero J Seoane J. Clinical Development of Therapies Targeting Tgfβ: Current Knowledge and Future Perspectives. Ann Oncol (2020 ) 31:1336–49

    Not in our library10.1016/j.annonc.2020.07.009

  128. 128.

    Greco R Qu H Qu H Theilhaber J Shapiro G Gregory R. Pan-Tgfβ Inhibition by SAR439459 Relieves Immunosuppression and Improves Antitumor Efficacy of PD-1 Blockade. Oncoimmunology (2020 ) 9:1811605–1811605

    Not in our library10.1080/2162402x.2020.1811605

  129. 129.

    Moffitt RA Marayati R Flate EL Volmar KE Loeza SGH Hoadley KA. Virtual Microdissection Identifies Distinct Tumor- and Stroma-Specific Subtypes of Pancreatic Ductal Adenocarcinoma. Nat Genet (2015 ) 47:1168–78

    Not in our library10.1038/ng.3398

  130. 130.

    Collisson EA Bailey P Chang DK Biankin AV. Molecular Subtypes of Pancreatic Cancer. Nat Rev Gastroenterol Hepatol (2019 ) 16:207–20

    Not in our library10.1038/s41575-019-0109-y

  131. 131.

    Elyada E Bolisetty M Laise P Flynn WF Courtois ET Burkhart RA. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discovery (2019 ) 9:1102–23

    Not in our library10.1158/2159-8290.cd-19-0094

  132. 132.

    Daemen A Peterson D Sahu N Mccord R Du X Liu B. Metabolite Profiling Stratifies Pancreatic Ductal Adenocarcinomas Into Subtypes With Distinct Sensitivities to Metabolic Inhibitors. Proc Natl Acad Sci (2015 ) 112:E4410

    Not in our library10.1073/pnas.1501605112

  133. 133.

    Ogawa Y Masugi Y Abe T Yamazaki K Ueno A Fujii-Nishimura Y. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen. Clin Cancer Res (2021 ) 27:107

    Not in our library10.1158/1078-0432.ccr-20-2298

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.